Lexaria Bioscience (LXRP) Stock Price, News & Analysis

Company Overview

Lexaria Bioscience Corp. operates in the drug delivery platform business. It develops and out-licenses its DehydraTECH technology for the delivery of bioactive compounds that promotes healthy ingestion methods, lower overall dosing, and higher effectiveness in active molecule delivery. The company has licensed DehydraTECH to various companies operating in the nicotine, pharmaceutical, nutraceutical, and vitamin industries. Lexaria Bioscience Corp. was founded in 2004 and is headquartered in Kelowna, Canada.

Key Stats

• Today's Range: N/A
• 50-Day Range: $0.22 to $0.22
• 52-Week Range: N/A
• Volume: 2.15 million shs
• Average Volume: 608,350 shs
• Market Capitalization: $20.15 million
• P/E Ratio: N/A
• Dividend Yield: N/A
• Price Target: N/A
• Consensus Rating: N/A

LXRP Stock Analysis - Frequently Asked Questions

How do I buy shares of Lexaria Bioscience?

Shares of LXRP stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Charles Schwab, E*TRADE, Fidelity, and Vanguard Brokerage Services.
Compare Top Brokerages Here.

What other stocks do shareholders of Lexaria Bioscience own?

Based on aggregate information from My MarketBeat watchlists, some other companies that Lexaria Bioscience investors own include Canopy Growth (CGC), Organigram (OGI), Walt Disney (DIS), Aurora Cannabis (ACBFF), Alibaba Group (BABA), Tilray (TLRY) and NVIDIA (NVDA).

Industry, Sector and Symbol

• Stock Exchange: OTCMKTS
• Sector: Medical
• Industry: Metal Mining
• Sub-Industry: N/A
• Current Symbol: OTCMKTS:LXRP
• CUSIP: 52886N208
• CIK: 1348362
• Web: www.lexariabioscience.com
• Phone: (250) 765-6424
• Fax: N/A
• Employees: 4
• Year Founded: N/A

Profitability

• EPS (Most Recent Fiscal Year): N/A
• Trailing P/E Ratio: N/A
• Forward P/E Ratio: N/A
• P/E Growth: N/A
• Net Income: $-4,090,000.00
• Net Margins: -1,046.77%
• Pretax Margin: N/A
• Return on Equity: -157.62%
• Return on Assets: -148.09%

Debt

• Debt-to-Equity Ratio: 0.01
• Current Ratio: 8.52
• Quick Ratio: 8.01

Sales & Book Value

• Annual Sales: $380,000.00
• Price / Sales: 0.00
• Cash Flow: N/A
• Price / Cash Flow: N/A
• Book Value: $0.03 per share
• Price / Book: N/A

Miscellaneous

• Outstanding Shares: 89,587,000
• Free Float: N/A
• Market Cap: $20.15 million
• Optionable: Not Optionable
• Beta: N/A